Compare Neurocrine Biosciences Inc (NBIX) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NextEra Energy, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while NextEra Energy, Inc. trades at $83 (market cap $172.41B). The key difference: NextEra Energy, Inc. is far larger — about 10.9× Neurocrine Biosciences Inc's market cap, and NextEra Energy, Inc. pays a 3.02% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NEE | |
|---|---|---|
Market Cap | $15.77B | $172.41B |
Sector | Health | Utilities |
52-Week High | $185.50 | $97.88 |
52-Week Low | $123.10 | $69.83 |
Enterprise Value | $15.78B | $279.74B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
NextEra Energy (NEE) trades at $83.83, showing modest daily gains of 0.48% amid a bearish technical outlook. The company demonstrates strong fundamentals with $27.4B revenue and 32.4% net margins in 2025, though recent Q4 2025 earnings missed expectations. Positive developments include securing a $1.9B DOE loan for nuclear plant restart and ongoing investor meetings. Analyst consensus remains strongly bullish with a $100.20 price target, representing 20% upside potential from current levels.
NEE presents a compelling long-term investment case with robust profitability and strategic growth initiatives in renewable energy and nuclear power. However, investors face risks from rising debt levels (47.6% debt-to-asset ratio) and recent technical weakness. The stock's current discount to analyst targets offers opportunity, but requires monitoring of execution on growth projects and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
